Whenever a new Ministerial Decree modifying pharmaceutical standards is enacted, regulatory affairs and quality assurance teams face an immediate wave of ambiguity. Following the official issuance of Farmakope Indonesia VI Suplemen IV, the industry’s response frequently fractures into two costly misconceptions: either over-complying out of caution or assuming complete immunity.
The first error stems from terminology: confusing “Suplemen IV” (the fourth official addendum to Indonesia’s pharmacopoeia) with a direct regulation on health supplements. The second error is assuming total exemption simply because health supplements are not explicitly cited within the decree.
The regulatory reality lies between these extremes. Farmakope Indonesia VI Suplemen IV legally binds manufacturers of drug substances and finished pharmaceutical products. Health supplement manufacturers are impacted only indirectly, specifically through the pharmaceutical-grade raw material mandates of PerBPOM 26/2025, and strictly for the dosage forms designated by BPOM.
Designed for Regulatory Affairs leads, Quality Assurance/Quality Control managers, brand owners, and importers across the health supplement and natural product sectors, this guide provides a precise breakdown of the monograph revisions, legal applicability, and the decision framework required to determine your actual compliance obligations.
Key Terms Used in This Article
| Term | Meaning |
|---|---|
| BPOM | Badan Pengawas Obat dan Makanan, Indonesia’s National Agency of Drug and Food Control |
| Kemenkes | Kementerian Kesehatan, the Ministry of Health |
| Farmalkes | The Ministry of Health’s Directorate General of Pharmaceutical and Medical Devices |
| KMK | Keputusan Menteri Kesehatan, a decision of the Minister of Health |
| PerBPOM | Peraturan BPOM, a regulation issued by BPOM |
| FI | Farmakope Indonesia, the Indonesian Pharmacopoeia, the official quality standard book for drugs and drug substances |
| Suplemen IV | The fourth addendum (supplement) to FI Edition VI. It is not a dietary supplement |
| Monograph | The official entry that defines identity, purity, and assay for one substance or product |
| CoA | Certificate of Analysis, the supplier document reporting a batch’s test results |
| ICP-OES | Inductively Coupled Plasma Optical Emission Spectrometry, an instrument technique for measuring trace elements |
| ICP-MS | Inductively Coupled Plasma Mass Spectrometry, an instrument technique that measures trace elements by mass |
| NIE | Nomor Izin Edar, the marketing authorisation number issued by BPOM |
| JDIH | Jaringan Dokumentasi dan Informasi Hukum, the national legal documentation network |
Farmakope Indonesia VI Suplemen IV: The Quick Answer
Farmakope Indonesia VI Suplemen IV is a Ministry of Health quality standard issued as KMK HK.01.07/MENKES/313/2026. It adds one monograph and revises 50 others. It binds businesses that make drug substances and drugs sold in Indonesia, who must meet it within 12 months of the decision.
Health supplements are not explicitly named: A supplement maker is affected only if their product utilizes pharmaceutical-grade raw materials required by PerBPOM 26/2025 for specific dosage forms. In that case, check raw-material certificates against the new monographs. If not, no action is due under this decision.
What Farmakope Indonesia VI Suplemen IV Is and What the Decision Says
A pharmacopoeia addendum, not a supplement rule
The Farmakope Indonesia (FI) is the official standard book for the quality of drugs and drug substances. Farmalkes lists KMK HK.01.07/MENKES/313/2026 on Suplemen IV of Farmakope Indonesia Edisi VI among its Kemenkes decisions, posted on 6 May 2026.
Here “Suplemen” means an addendum to the book, in the same way earlier supplements amended FI Edition VI. It does not mean dietary supplement. In our experience, this one translation issue explains most of the confusion we see when the decision circulates among brand owners.
Who must meet it, and by when
Under KMK HK.01.07/MENKES/313/2026, businesses that make drug substances and drugs sold in Indonesia are responsible for meeting the standard within 12 months of the decision, starting from April 17, 2026.
Any calendar deadline should be read from the decision text itself and confirmed with a regulatory adviser before it enters a compliance plan. Counting errors on “months from the decision” are easy to make and expensive to correct later.
What Changed in Farmakope Indonesia VI Suplemen IV
The changes are technical and concentrated in testing. The table summarises the new and revised monographs in KMK HK.01.07/MENKES/313/2026. Because one monograph can change in several ways, the rows overlap and should not be added together, and each change can alter what a certificate must show.
| Change | Monographs | What it means in practice |
|---|---|---|
| New monograph (astaxanthin esters) | 1 | A new official standard now exists for this substance |
| Revised monographs | 50 | Each revised entry should be matched against the raw materials you actually use |
| Assay changed | 41 | The content test method or its limits differ from the previous text |
| Organic-impurity tests changed | 31 | The impurity profile and its test method may differ |
| Heavy-metals test removed | 15 | Elemental impurities are handled under General Provision 5.6.3 |
| Dissolution test changed | 13 | Alternative methods need verification or validation |
Assay and organic-impurity tests
Fourty one of the 50 revised monographs change the assay, and 31 change the organic-impurity tests. For a raw-material buyer, this means the method behind a certificate of analysis (CoA) may no longer match the current monograph, even when the reported numbers look unchanged.
Heavy metals and elemental impurities
Fifteen monographs lose the heavy-metals test. Elemental impurities are handled under General Provision 5.6.3, supported by a new appendix on ICP-OES and ICP-MS. Our reading is a shift from a classic limit test toward instrument-based measurement of individual elements.
Dissolution and alternative methods
Dissolution tests change in 13 monographs. Alternative methods now need verification or validation under appendices <1382> and <1381>. Dissolution is a release test for finished dosage forms such as tablets and capsules, so this change matters less for plain raw materials.
Who Is Bound by Farmakope Indonesia VI Suplemen IV?
The decision places the responsibility on businesses that make drug substances and drugs sold in Indonesia. Everyone else sits in a different position. The table separates who is bound, who may be reached indirectly, and who should simply watch.
| Who | Position | Why |
|---|---|---|
| Makers of drug substances sold in Indonesia | Bound | Named as responsible for meeting the standard |
| Makers of drugs sold in Indonesia | Bound | Named as responsible for meeting the standard |
| Supplement makers whose use pharmaceutical-grade ingredients | Reached indirectly: check | Through PerBPOM 26/2025, not through the decision itself |
| Supplement makers not using pharmaceutical-grade ingredients | Watch only | Not named in the decision and no PerBPOM 26/2025 trigger |
| Importers and distributors of drug substances | Confirm with an adviser | Position depends on their role and on who holds responsibility for the product |
Our reading is that most supplement makers sit in the last two rows. Only by examining the raw materials used for each product can tell you which row is yours. That check is where we are most often asked to help, because the answer decides whether any work follows.
How Suplemen IV Can Reach a Supplement Maker Through PerBPOM 26/2025
What PerBPOM 26/2025 requires
Peraturan BPOM Nomor 26 Tahun 2025 on risk assessment of raw materials took effect on 3 October 2025, as recorded by the JDIH database of BPK. It requires ingredients in certain dosage forms of natural medicines, supplements, quasi-drugs, and cosmetics to meet pharmaceutical-ingredient standards.
The rule applies only to dosage forms that BPOM identifies through its risk assessment, and the official text leaves the list of pharmaceutical raw materials to BPOM. Our reading is simple: no listed dosage form, no pharmaceutical-grade obligation under this rule.
The list decision from BPOM
BPOM has since issued Keputusan Kepala BPOM Nomor 366 Tahun 2026 on the list of pharmaceutical raw materials used in these product groups. We understand it was issued on 27 July 2026.
Our reading: the link from the decision to your CoA
Our reading is that a pharmaceutical-grade benchmark can point to pharmacopoeial monographs, which would make Suplemen IV relevant to listed raw materials that have an FI monograph. PerBPOM 26/2025 does not itself say so, which makes this an interpretation, not a stated rule.
What We See in Raw-Material Certificate Files
In our experience, the earliest sign of an out-of-date raw-material file is not a wrong number. It is a CoA whose test list still shows a heavy-metals limit test for a substance whose monograph no longer carries it, or an assay method that names no pharmacopoeial edition.
“Pharmaceutical grade” is a label suppliers often apply loosely. What counts is whether the certificate can be traced to a named monograph, edition, and supplement. That traceability question is usually the one that separates a file that holds up from a file that needs rework.
Questions to prepare for your adviser
These questions are meant to organise a conversation with a regulatory adviser. They are not a self-certification tool, because reading a CoA against a revised monograph is a technical judgement that depends on the full file, the dosage form, and the supplier’s testing records.
- Which monograph, edition, and supplement does each CoA cite?
- Does the CoA still report a heavy-metals limit test that a revised monograph has dropped?
- Does the assay or impurity method on the CoA match the revised monograph?
- Is your dosage form among those BPOM lists for pharmaceutical-grade ingredients?
- Who in your supply chain holds responsibility for each raw material?
Health Supplement Registration Indonesia: Where This Fits
Health supplement registration in Indonesia is BPOM’s pre-market process under Peraturan BPOM Nomor 32 Tahun 2022 on registration of health supplements, as amended by Peraturan BPOM Nomor 15 Tahun 2024. A business files safety, benefit, and quality evidence and receives an NIE before sale.
BPOM reported 6,173 health supplements with valid marketing authorisation as of 15 April 2025. That is a large register, and every file on it rests on a quality section. Suplemen IV adds no new registration step, but raw-material evidence is one strand of that section.
Other strands have their own rules. Our guide to PerBPOM 6/2025 stability testing covers shelf-life evidence, and our article on the PerBPOM 27/2025 facility audit covers what verifiers check on site. For live-organism products, see our probiotic supplement registration guide.
Our Health Supplements Registration service supports supplement dossiers from category check to submission. Raw-material questions raised by this decision are best settled inside that review, before filing or renewal, rather than during an evaluation, when time pressure narrows your options.
Decision Path: Does Suplemen IV Apply to Your Product?
Use this path to prepare questions for your adviser, not to self-certify. Each answer depends on the specific product, dosage form, and raw material, so an unclear answer at any step is a reason to ask for a review rather than to guess.
- Do you make drug substances or drugs sold in Indonesia? If yes, the decision binds you directly. Confirm which monographs apply to your products.
- Is your product a health supplement? If yes, continue to the next question.
- Is its raw materials among those BPOM lists under PerBPOM 26/2025? If no, no action is due under this decision.
- If yes, do your raw-material certificates cite the relevant monograph, and is the test method current? Ask a regulatory adviser to review them.
- Is any answer unclear? Request a regulatory review before you change a specification or file.
Limits of This Guidance
This article explains scope, not your obligations. It does not list every changed monograph, set a deadline, or replace legal advice. Whether a product sits in a listed dosage form, and what a revised monograph means for a raw material, depends on your specific file.
Interpretations can change over time. Confirm the current text of KMK HK.01.07/MENKES/313/2026 and PerBPOM 26/2025 with Kemenkes and BPOM, or with a qualified regulatory adviser, before acting on anything described here or changing any specification, supplier, or product label.
Conclusion: Know Where You Stand Before It Matters
The encouraging news is that Farmakope Indonesia VI Suplemen IV rarely creates work for supplement makers, and one question settles most cases. Asking it early, calmly, and with the right documents costs far less than discovering a gap in the middle of an evaluation.
Product Registration Indonesia can check whether your dosage forms fall under PerBPOM 26/2025, review raw-material certificates against current monographs, and tell you where action is, or is not, needed. That protects you from both unnecessary rework and missed obligations.
Book a Health Supplements Registration consultation. Not sure whether your dosage forms fall under PerBPOM 26/2025, or what your raw-material certificates should cite? Fill out the contact form below, and our regulatory advisers will review your product list and certificates with you before any filing or renewal.
